Dr. Maryam Moinfar, MD

Dr. Moinfar practices at Advanced Dermatology Of San Clemente INC in Dana Point, California.

Dr. Moinfar's NPI, 1376515403, was assigned on February 2, 2006. Dr. Moinfar graduated from Feinberg School of Medicine in 2001. Dr. Moinfar's California license number on file is A92449.

Dr. Moinfar's primary practice is Advanced Dermatology of San Clemente INC, at 34213 Pacific Coast Hwy, Dana Point, CA 92629-2875. The practice phone is (949) 248-4547.

Dr. Moinfar's primary practice is Advanced Dermatology Of San Clemente INC in Dana Point, California. The medical group on file is Advanced Dermatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moinfar practices. Vendor and product names are available with a free account.

Dermatology is Dr. Moinfar's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Moinfar is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Moinfar's licenses on file in 2 states: California and Minnesota.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, itchy rashes, psoriasis and rash among the conditions Dr. Moinfar treats.

CMS data shows 21,859 Medicare services from Dr. Moinfar across 36 procedure codes in 2024, for 820 Medicare patients. Medicare paid $610,385 for them. Every service was in an office.

CMS counts 820 Medicare patients who saw Dr. Moinfar in 2024. The largest group is 65 to 74, with 387 patients. 75% of them have high cholesterol, and 60% have high blood pressure. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Moinfar's median patient age at 64, with 59% women.

In 2024, Dr. Moinfar wrote 426 Medicare Part D claims for 191 patients. 92% of them were for generic drugs. CMS names the drug for 269 of them, across 8 drugs with 11 or more claims each, at $5,590 in total drug cost. In 2023, CMS named 310 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Moinfar for performance year 2024, reported as part of a group. Dr. Moinfar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Moinfar as offering telehealth. CMS counts 4,187 procedures of removal of skin lesions by Dr. Moinfar, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Moinfar.

CMS Open Payments shows 367 general payments to Dr. Moinfar from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Sun Pharmaceutical Industries Inc. paid the most, $762.

Dmand AI lists 2 awards for Dr. Moinfar, most recently CMS Stage 1 EHR in 2013.

Dr. Moinfar graduated from Feinberg School of Medicine in 2001. Dr. Moinfar is a member of AAD.

Dr. Moinfar is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.